Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.87 HKD | +1.04% | -1.22% | +19.07% |
04/06 | Grand Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2023 | CI |
29/04 | Grand Pharmaceutical's Profit Down 10% in 2023 Despite 10% Revenue Jump | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Its low valuation, with P/E ratio at 7.73 and 6.76 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The company appears to be poorly valued given its net asset value.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- This company will be of major interest to investors in search of a high dividend stock.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Weaknesses
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+19.07% | 218.31Cr | - | ||
+47.33% | 77TCr | C+ | ||
-6.76% | 35TCr | C+ | ||
+19.49% | 33TCr | B- | ||
+8.69% | 30TCr | C+ | ||
+18.87% | 25TCr | B+ | ||
-1.96% | 22TCr | A+ | ||
+11.11% | 22TCr | B- | ||
+4.78% | 16TCr | C+ | ||
-2.47% | 16TCr | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 512 Stock
- Ratings Grand Pharmaceutical Group Limited